Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer

<sup>177</sup>Lu-PSMA-617 radioligand therapy (<sup>177</sup>Lu-PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) currently consists of 4–6 cycles of 6.0–7.4 GBq of <sup>177</sup>Lu-PSMA-617 each every 6–8 weeks. While safety and e...

Full description

Bibliographic Details
Main Authors:	Nicolai Mader, Christina Schoeler, Niloufar Pezeshkpour, Konrad Klimek, Daniel Groener, Christian Happel, Nikolaos Tselis, Philipp Mandel, Frank Grünwald, Amir Sabet
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Cancers
Subjects:	prostate-specific membrane antigen (PSMA) <sup>177</sup>Lu-PSMA-617 radioligand therapy (RLT) intermittent treatment metastatic castration-resistant prostate cancer (mCRPC)
Online Access:	https://www.mdpi.com/2072-6694/15/18/4605

Similar Items

Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-Dichloride
by: Justus Baumgarten, et al.
Published: (2022-01-01)

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
by: Felix Kind, et al.
Published: (2021-12-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
by: Daniel Groener, et al.
Published: (2023-01-01)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01)

Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT
by: Daniel Groener, et al.
Published: (2023-07-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

Comparative Analysis of Morphological and Functional Effects of <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands
by: Benedikt Feuerecker, et al.
Published: (2023-11-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023-05-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
by: Florian Rosar, et al.
Published: (2022-05-01)

Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
by: Yuanzhuo Yan, et al.
Published: (2024-03-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023-11-01)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
by: Thomas Langbein, et al.
Published: (2022-08-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
by: Felix Kind, et al.
Published: (2022-04-01)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Robin Wrenger, et al.
Published: (2022-07-01)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics
by: Jason P. Meier, et al.
Published: (2023-08-01)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [<sup>68</sup>Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [<sup>68</sup>Ga]Ga-PSMA-11
by: René Fernández, et al.
Published: (2023-12-01)

<sup>177</sup>Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α<sub>1</sub>-Microglobulin (A1M), Including Kidney Damage Assessment Using <sup>99m</sup>Tc-MAG3 Imaging
by: Amanda Kristiansson, et al.
Published: (2021-02-01)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
by: Julia Brosch-Lenz, et al.
Published: (2021-03-01)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01)

Quality Assurance Investigations and Impurity Characterization during Upscaling of [<sup>177</sup>Lu]Lu-PSMA<sup>I&T</sup>
by: Stefan Schmitl, et al.
Published: (2023-11-01)